Castle Biosciences (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Brokerages

Share on StockTwits

Castle Biosciences (NASDAQ:CSTL) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $31.60.

A number of research analysts have commented on CSTL shares. Leerink Swann set a $33.00 price objective on shares of Castle Biosciences and gave the company a “buy” rating in a research note on Wednesday, September 4th. Zacks Investment Research lowered shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Monday. Canaccord Genuity boosted their price target on shares of Castle Biosciences from $26.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Robert W. Baird boosted their price target on shares of Castle Biosciences from $27.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. Finally, BTIG Research boosted their price target on shares of Castle Biosciences to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th.

In other news, major shareholder Mgc Venture Partners 2013 Gp, purchased 312,500 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David S. Kabakoff purchased 62,500 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here.

NASDAQ CSTL traded up $0.17 during trading on Monday, reaching $18.91. The company’s stock had a trading volume of 101,700 shares, compared to its average volume of 137,228. Castle Biosciences has a twelve month low of $16.78 and a twelve month high of $28.50. The business’s fifty day moving average is $21.18.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.54). The business had revenue of $10.74 million for the quarter, compared to the consensus estimate of $7.06 million. Research analysts anticipate that Castle Biosciences will post -1.57 EPS for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Recommended Story: What are the benefits of buying treasury bonds?

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cal-Maine Foods  Upgraded at BidaskClub
Cal-Maine Foods Upgraded at BidaskClub
GrubHub  Lifted to Overweight at Barclays
GrubHub Lifted to Overweight at Barclays
Emerson Electric  Downgraded by HSBC
Emerson Electric Downgraded by HSBC
PotCoin  Hits 24 Hour Volume of $73.00
PotCoin Hits 24 Hour Volume of $73.00
Ambarella Inc  Receives $60.13 Consensus Price Target from Analysts
Ambarella Inc Receives $60.13 Consensus Price Target from Analysts
Brokerages Set Mylan NV  Target Price at $27.59
Brokerages Set Mylan NV Target Price at $27.59


© 2006-2019 Ticker Report